Aurion BioTech presents cell therapy findings with published clinical data

Conferences|ASCRS

Greg Kunst, president and CEO of Aurion BioTech, shares a company update on endothelial cell therapy trials, clinical plans and upcoming data.

Related Videos
Related Content

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

Uveitis, flare ups and challenges in clinical trials

April 12th 2022

Intergalactic Therapeutics announces positive preclinical results of Its platform in ABCA4 retinopathies

March 15th 2023

The changing landscape of gene therapy and standardized endpoints

February 23rd 2022

Large-scale study enables new insights into rare eye disorders

March 11th 2023

Exploring developments in gene therapy for inherited optic neuropathies

March 11th 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

Uveitis, flare ups and challenges in clinical trials

April 12th 2022

Intergalactic Therapeutics announces positive preclinical results of Its platform in ABCA4 retinopathies

March 15th 2023

The changing landscape of gene therapy and standardized endpoints

February 23rd 2022

Large-scale study enables new insights into rare eye disorders

March 11th 2023

Exploring developments in gene therapy for inherited optic neuropathies

March 11th 2023

Evidence-based debates and discussions at COPHy 2023

March 21st 2023

Uveitis, flare ups and challenges in clinical trials

April 12th 2022

Intergalactic Therapeutics announces positive preclinical results of Its platform in ABCA4 retinopathies

March 15th 2023

The changing landscape of gene therapy and standardized endpoints

February 23rd 2022

Large-scale study enables new insights into rare eye disorders

March 11th 2023

Exploring developments in gene therapy for inherited optic neuropathies

March 11th 2023
© 2023 MJH Life Sciences

All rights reserved.